Martin Vogelbaum is a Corporate Vice President of Business Development at Celgene Corporation. Mr. Vogelbaum has over 22 years of experience as a life sciences venture capitalist having been involved with companies at all stages of development including co-founding several start-ups. Prior to joining Celgene, he served as a partner at Rho Ventures from 2005-2015 where he primarily focused on investments in biotechnology, biopharmaceuticals and medical devices. Some representative investments included Cara (CARA), Gloucester Pharmaceuticals (sold to Celgene), SARcode Biosciences (sold to Shire), AqueSys (sold to Allergan) and Mersana Therapeutics. Prior to Rho, he was a partner at Apple Tree Partners, a life sciences venture firm focused on early-stage companies.
He began his venture capital career in 1993 at Oxford Bioscience Partners, where he served as a general partner. Prior to Oxford, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD). Mr. Vogelbaum received his A.B. in biology and history from Columbia University. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation.